Capital Cell sigue invirtiendo en Biomedicina

Integral service around a transaction
BY : Diego Gutiérrez08/10/2020

Capital Cell es la primera plataforma de inversión online de Europa especializada en biomedicina. A pesar de la pandemia global del coronavirus, ha movido 4 millones de euros de inversión para 4 empresas en el primer trimestre de 2020. La crisis del coronavirus está castigando fuertemente la economía global y especialmente, la de nuestro país.  

Tras un trimestre duro para los mercados, los fondos de inversión se han decantado por apostar por las empresas de alta tecnología biomédica, un sector en plena eclosión en España. Este es el caso de Cell Capital.  

La biotecnología, el único sector que se salva 

Según comenta Daniel Oliver, CEO de Capital Cell “En un contexto como el actual, la importancia de la biotecnología pasa de ser estratégica a ser urgente, y se va a afianzar como uno de los sectores de inversión más deseados”. Solo la inversión realizada por Capital Cell representaría más del 12% del total de inversión realizada en el sector de la biotecnología en España en el 2018, que ascendió a 98 millones de euros según la Asociación Española de Empresas de Biotecnología. 

No obstante, no sólo España registra un crecimiento de la inversión en biotecnología. Entre febrero y marzo, el sector biotecnológico ha supuesto la inversión con mayor rentabilidad del índice NASDAQ estadounidense, mientras la mayoría de los sectores de inversión, incluyendo el financiero, la energía o el inmobiliario, registran desplomes históricos. 

Capital Cell no pierde el ritmo 

La plataforma de inversión ‘online’ especializada en biomedicina ha invertido durante el primer trimestre de este año cuatro millones de euros en cuatro empresas del sector biotecnológico, lo que supone un 37% más que en el mismo periodo del año anterior. También es más de un tercio del total invertido el año pasado, ya que se movieron 11,6 millones de euros en el 2019. 

Por ejemplo, desde el comienzo del confinamiento por la crisis del Covid-19, Capital Cell ha conseguido lanzar y cerrar con éxito una ronda de inversión de 560.000 euros para la empresa valenciana de sistema de diagnóstico digital eKuore. También otras start ups como Aortyx – de la cual ya se habló en un anterior post–  Devicare o Ability Pharma han confirmado inversiones por valor superior a los 6 millones de euros. 

The M&A Professionals

Meet our services

MEET
OUR
metodologY

Do you want to be up to date?

SUSCRIBE OUR NEWSLETTER

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
"Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu